New Report, Same Theme On US FDA's Policy On Cannabidiols: ‘Extensive Data Gaps’ On Safety

FDA’s second report to Congress on oversight of CBD market includes results from studies of whether products are mislabeled or adulterated, but also indicates throughout that more data are needed on safety of hemp-derived CBD ingredients used in myriad consumer health, cosmetic and food products already available.

The US Food and Drug Administration’s latest report to Congress on opening a regulatory pathway for using cannabidiols in products other than drugs makes clear that an additional $5m to support the work that House appropriators propose for the agency’s fiscal 2021 budget is needed.

While the FDA’s second report in 2020 to Congress on its oversight of CBD manufacturing and marketing includes results...